Search PubMed⌕ Search

Biomedical subjects

G Vogel

Publications and source records attributed to G Vogel.

At least 19 recordsLinked to original sources

Interaction between bunk management and monensin concentration on finishing performance, feeding behavior, and ruminal metabolism during an acidosis challenge with feedlot cattle.

Two commercial feedlot experiments and a metabolism study were conducted to evaluate the effects of monensin concentrations and bunk management strategies on performance, feed intake, and ruminal metabolism. In the feedlot experiments, 1,793 and 1,615 steers were used in Exp. 1 and 2, respectively, in 18 pens for each experiment (six pens/treatment). Three treatments were evaluated: 1) ad libitum bunk management with 28.6 mg/kg monensin and clean bunk management strategies with either 2) 28.6 or 3) 36.3 mg/kg monensin. In both experiments, 54 to 59% of the clean bunk pens were clean at targeted clean time, or 2200, compared with 24 to 28% of the ad libitum pens. However, only 13% of the pens were clean by 2000 in Exp. 1 (summer), whereas 44% of the pens in Exp. 2 (winter) were clean by 2000. In Exp. 1, bunk management and monensin concentration did not affect carcass-adjusted performance. In Exp. 2, steers fed ad libitum had greater DMI (P < 0.01) and carcass-adjusted ADG (P < 0.01) but feed efficiency (P > 0.13) similar to that of clean bunk-fed steers. Monensin concentration had no effect on carcass-adjusted performance (P > 0.20) in either experiment. A metabolism experiment was conducted with eight fistulated steers in a replicated 4 x 4 Latin square acidosis challenge experiment. An acidosis challenge was imposed by feeding 125% of the previous day's DMI, 4 h later than normal. Treatments consisted of monensin concentrations (mg/kg) of 0, 36.7, 48.9, or 36.7 until challenged and switched to 48.9 on the challenge day and 4 d following. Each replicate of the Latin square was managed with separate bunk management strategies (clean bunk or ad libitum). Feeding any concentration of monensin increased number of meals and decreased DMI rate (%/h) (P < 0.12) for the 4 d following the acidosis challenge. Meal size, pH change, and pH variance were lower (P < 0.10) for steers fed monensin with clean bunk management. However, no monensin effect was observed for steers fed ad libitum. Bunk management strategy has the potential to decrease DMI and ADG when steers managed on a clean bunk program are restricted relative to traditional, ad libitum bunk programs. Monensin helps control intake patterns for individuals, but increasing concentration above currently approved levels in this study seemed to have little effect.

Acidosis↗

Long-term clinical effectiveness of oral implants in the treatment of partial edentulism. Seven-year life table analysis of a prospective study with ITI dental implants system used for single-tooth restorations.

One hundred and eight-seven ITI implants were prospectively followed from November 1992 to July 2000, in order to evaluate the clinical efficiency and the long-term prognosis in 109 partially edentulous patients (69 women and 40 men; average age 41.3 years). Of these 187 implants, 69.5% were placed in the mandible and 30.5% in the maxilla. After a healing period that ranged from three to six months, the osseointegrated implants (n = 184) were restored with single crowns. Three implants were extracted prior to loading the fixture and were considered early failures. Each implant was reassessed on a yearly basis, both clinically and radiographically. The results of the investigation, which were evaluated according to predefined success criteria, were reviewed in accordance with a life table method. During the follow-up, six cases were deemed to be late failures. In each of these cases, a suppurative infection of the peri-implant tissue was diagnosed: in one implant, the infection could not be eradicated and the implant was removed. When 11 drop-outs were included in the analysis, the cumulative survival and success rates for the whole sample group were 96.77% and 93.6%, respectively. When only prosthetically loaded implants were considered, the results increased to 99.35% for the cumulative survival rate and 96.18% for the cumulative success rate. The analysis on disaggregated data showed better results for maxillary restorations (survival rate 100%) in comparison to mandible restorations (survival rate 95.11%). It was concluded that, under standard anatomic conditions (bone site height > 8 mm, thickness > 6 mm), prosthetic restoration of partially edentulous patients with the ITI system can be described as a reliable and efficient therapy in the long term.

Adult↗

Regiospecific phosphohydrolases from Dictyostelium as tools for the chemoenzymatic synthesis of the enantiomers D-myo-inositol 1,2,4-trisphosphate and D-myo-inositol 2,3,6-trisphosphate: non-physiological, potential analogues of biologically active D-myo-inositol 1,3,4-trisphosphate.

A new de novo synthesis of the enantiomeric pair D-myo-inositol 1,2,4-trisphosphate and D-myo-inositol 2,3,6-trisphosphate is described. Starting from enantiopure dibromocyclohexenediol, several C2 symmetrical building blocks were synthesized which gave access to D-myo-inositol 1,2,4,5-tetrakisphosphate and D-myo-inositol 1,2,3,6-tetrakisphosphate. Exploiting the high regiospecificity of two partially purified phosphohydrolases from Dictyostelium, a 5-phosphatase and a phytase, the inositol tetrakisphosphates were converted enzymatically to the target compounds. Their potential to modulate the activity of Ins3,4,5,6P4 1-kinase was investigated and compared with the effects of D-myo-inositol 1,3,4-trisphosphate.

Animals↗

Stem cell research. Reports give green light in Australia, Israel.

BERLIN AND MELBOURNE--After 2 years of deliberation, an Australian government committee has endorsed legislation that would allow both human embryonic stem cell research and the derivation of ES cells from unwanted embryos created during fertility treatments. And in Israel, another country at the forefront of work on ES cells, a national bioethics committee has approved both the derivation of ES cells and research into therapeutic cloning.

Australia↗